Since unaffordability and lack of access preclude the assessment of multiple immunopathological and molecular markers in SSA, a consensus was reached that in resource-limited settings, the combination of characteristic clinical findings, morphologic appearance on hematoxylin and eosin staining, and a positive CD3 or CD4 immunohistochemical result is sufficient for diagnosing MF [7]. This evidence concerns the gene CD4 and mycosis fungoides.